Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mid-Sized Japan Makers to Take Heaviest Hit from April Price Cut, Bigger Peers See Smaller Reductions: Jiho Survey
March 7, 2018
- Average NHI Price Reduction Rate of 12.8% for 3 Major Generic Makers: Jiho Tally
March 7, 2018
- Astellas, Tottori Univ. Pair Up to Develop, Commercialize Immunostimulating Gene Loading Oncolytic Virus
March 7, 2018
- Takeda Consumer Healthcare President Sugimoto to Step Down following 1 Year Stint since Firm’s Inception
March 7, 2018
- Alcon Pharma Reorganizes Marketing System to Boost Market Shares of Major Products including Lucentis
March 5, 2018
- Japan Ethical Drug Sales Slip 1.0% in 2017, Harvoni Drops Out of Top 10 List: IQVIA
March 2, 2018
- World’s 1st Commercial Manufacturing Plant for Allogeneic iPSC Therapies Completed: Sumitomo Dainippon
March 2, 2018
- Canaglu Launched in Taiwan: Mitsubishi Tanabe
March 2, 2018
- Galderma Completes Transfer of Japan Rozex Rights to Maruho
March 2, 2018
- Pfizer to Copromote Effexor SR with Sumitomo Dainippon
March 2, 2018
- Daiichi Sankyo US Subsidiary to Restructure Sales Unit with 280 Job Culls, Anticipating Launch of Oncology Agents
March 2, 2018
- Despite Solid Mainstays, Pfizer Japan’s FY2017 Sales Down 6.6% on LLPs
March 2, 2018
- Valixa’s Pediatric Indication Filed for CMV Infection in Organ Transplant
March 1, 2018
- Kaken Grants Rights for Psoriasis Drug Candidate to Valeant
March 1, 2018
- MSD Seeks Japan Approval of Broad-Spectrum Antibiotic
March 1, 2018
- Takeda Files Japan NDA for Relugolix in Uterine Fibroids
March 1, 2018
- Janssen, Japan IBD Society Ink MOU on Crohn’s Disease Registry Study
March 1, 2018
- Hisamitsu’s Transdermal Parkinson’s Drug Hits Primary Endpoint
February 28, 2018
- FDA, EMA Accept Lusutrombopag Submissions, Priority Status Given in US: Shionogi
February 28, 2018
- Daiichi Sankyo Seeks Japan Approval for Hypertension Med Esaxerenone
February 28, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…